DOCSLIB.ORG

Ketamine for Perioperative Pain Management Sabine Himmelseher, M.D.,* Marcel E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ketamine for Perioperative Pain Management Sabine Himmelseher, M.D.,* Marcel E Ⅵ CLINICAL CONCEPTS AND COMMENTARY Richard B. Weiskopf, M.D., Editor Anesthesiology 2005; 102:211–20 © 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Ketamine for Perioperative Pain Management Sabine Himmelseher, M.D.,* Marcel E. Durieux, M.D., Ph.D.† AS part of the effort to develop mechanisms-based ap- Anti-nociceptive Therapy with Ketamine proaches to pain therapy, renewed interest has focused during Anesthesia on the use of ketamine for treatment of acute and Intravenous Ketamine as an Analgesic Adjunct to chronic pain. In particular, the role of N-methyl-D-aspar- General Anesthesia tate (NMDA) excitatory glutamate receptors in nocicep- Intravenous subanesthetic ketamine, when added as tive transmission has been established in humans.1–3 an adjunct to general anesthesia, reduced postoperative NMDA receptors participate in the development and pain and opioid requirements in a variety of settings, maintenance of what can be called “pathologic pain” from outpatient surgery to major abdominal procedures after tissue injury: increased pain perception as a result (level II evidence) (table 1).9–16 However, some studies of pain sensitization, in part from synaptic plasticity.1–3 did not show this benefit (level II evidence) (table Ketamine binds noncompetitively to the phencyclidine 1).17,18 Two factors may explain these failures. First, binding site of NMDA receptors4 but also modifies them beneficial effects of ketamine may be masked when the via allosteric mechanisms.5 When studied at subanes- drug is used in small doses (Ͻ0.15 mg/kg) against the thetic doses, its analgesic efficacy correlates well with its background of multimodal or epidural analgesia.17 Sec- inhibiting action on NMDA receptor-mediated pain facil- ond, the dosing schedule may be inadequate. Studies itation4,6 and a decrease in activity of brain structures have compared the effects of ketamine administration that respond to noxious stimuli.7 Ketamine therefore before surgery with those of one ketamine administra- represents a promising modality in several perioperative tion at the end of surgery to test its “preemptive” anal- strategies to prevent pathologic pain. gesic properties. However, nociceptive and inflamma- Another reason for the renewed interest in ketamine is tory signals are generated throughout surgery and after the availability of S(ϩ) ketamine. Ketamine has a chiral center at the carbon-2 atom of the cyclohexanone ring, the procedure. A single injection of a short-acting drug and therefore exists as the optical stereoisomers S(ϩ) such as ketamine either before or after incision will 4 therefore not provide analgesia that lasts far into the and R(-) ketamine. Until recently, ketamine was mar- 18 keted as a racemate, containing equimolar amounts of postoperative period. To prevent pathologic pain, ket- the enantiomers. S(ϩ) ketamine has a fourfold greater amine needs to be applied at least throughout the oper- affinity for NMDA receptors than does R(-) ketamine.4 ation and likely for a period of time into the postopera- This difference results in a clinical analgesic potency of tive phase, in an attempt to reduce sensitization of S(ϩ) ketamine approximately two times greater than central and peripheral pain pathways. Thus, the ade- that of racemic and four times greater than that of R(-) quacy of the ketamine administration schedule is a cru- ketamine, whereas S(ϩ) ketamine has a shorter duration cial component for pain prevention (fig. 1). of action.4,6,8 Dosing of ketamine when used for this purpose is We discuss the perioperative use of ketamine as an affected by variety of factors, including the expected adjunct to general and regional anesthesia and to post- amount of pain, whether general or epidural anesthesia operative pain therapy. Focus will be on the administra- will be used, and whether ketamine will be applied tion of the drug at subanesthetic concentrations; we will intraoperatively or intraoperatively and postoperatively refer to this as “subanesthetic ketamine.” (level II evidence) (table 1). In a long-term outcome trial on adenocarcinoma surgery with general or epidural anesthesia, racemic ketamine injected as a 0.5 mg/kg preincisional bolus followed by an infusion of * Anesthesiologist, Klinik fuer Anaesthesiologie, Klinikum rechts der Isar, Ϫ1 Ϫ1 Technische Universität München, Germany; † Professor, Department of Anesthe- 0.25 mg·kg ·h reduced postoperative morphine siology, University of Virginia Health System, Charlottesville, Virginia. needs and the incidence of residual pain until the sixth Received from the Department of Anesthesiology, University of Virginia postoperative month.13 However, this was not the case Health System, Charlottesville, Virginia. Submitted for publication February 25, 2004. Accepted for publication June 24, 2004. Support for this research was when the drug was used at half the dose. After gastrec- provided solely from institutional and/or departmental sources. tomy12 or major renal surgery14 with general or epidural Address reprint requests to Dr. Durieux: Department of Anesthesiology, Uni- versity of Virginia, P.O. Box 800710, Charlottesville, VA 22908-0710. Address anesthesia, ketamine improved postoperative pain relief Ϫ1 Ϫ1 electronic mail to: [email protected]. after an intraoperative infusion of 500 ␮g·kg ·h pre- Anesthesiology, V 102, No 1, Jan 2005 211 212 S. HIMMELSEHER AND M. E. DURIEUX Anesthesiology, V 102, No 1, Jan 2005 KETAMINE FOR PERIOPERATIVE PAIN MANAGEMENT 213 Fig. 1. For prevention of pathologic pain after severe tissue injury, ketamine ad- ministration should cover the entire du- ration of high-intensity noxious and in- flammatory stimulation, not simply the initial trauma. N-methyl-D-aspartate recep- tors should be blocked during ongoing intraoperative as well as postoperative transmission of nociceptive impulses. Postoperative mobilization may elicit de- layed waves of afferent painful stimuli. Re- garding acute opiate tolerance-related phe- nomena, it is as yet unclear whether ketamine is best administered before first use of opioids. ceded by a preincisional bolus of 1 mg/kg14 or 0.5 mg/kg.12 S(ϩ) ketamine bolus and an intraoperative infusion of In patients undergoing major pelvic visceral procedures 120 ␮g·kgϪ1·hϪ1, followed by patient-controlled analgesia with general or epidural anesthesia, we found less postop- (PCA) with boluses of 1 mg morphine and 0.5 mg S(ϩ) erative pain when 0.5 mg/kg preincisional S(ϩ) ketamine ketamine.15 In less painful surgery such as nephrectomy, was followed by repeated 0.2 mg/kg boluses, as compared a preincisional bolus of 0.5 mg racemic ketamine fol- with preincisional S(ϩ) ketamine alone.16 After radical lowed by a 24 h-infusion of 120 ␮g·kgϪ1·hϪ1 and then of prostatectomy with general anesthesia, opiate needs and 60 ␮g·kgϪ1·hϪ1 for 48 h reduced hyperalgesia surround- pain at rest were reduced after a 0.1 mg/kg preoperative ing the incision.11 Anesthesiology, V 102, No 1, Jan 2005 214 S. HIMMELSEHER AND M. E. DURIEUX The following dosing schedule can therefore be pro- caudal use, ketamine gains rapid access to the systemic posed: In painful procedures, a 0.5 mg/kg slow bolus circulation with high bioavailability (level III evi- injection of ketamine before or after induction of general dence).29–31 After preoperative use in children, caudal anesthesia, but before incision, may be used; this may be S(ϩ) ketamine reduced postoperative pain better than followed by repeated injections of 0.25 mg/kg ketamine intramuscular29 or intravenous S(ϩ) ketamine.30 As at 30-min time intervals or a continuous infusion of plasma concentrations are mostly similar after caudal 500 ␮g·kgϪ1·hϪ1. For procedures lasting longer than 2 h, and intramuscular ketamine,29 this benefit likely resulted drug administration ends at least 60 min before surgery from neuroaxial rather than systemic action. When to prevent prolonged recovery. In procedures expected 0.5 mg/kg epidural versus 0.5 mg/kg intravenous race- to be less painful, a 0.25 mg/kg ketamine bolus before mic ketamine were compared in adults undergoing gas- incision may be injected; this may be followed by 30-min trectomy, less postoperative pain was also found after injections of 0.125 mg/kg ketamine or an infusion of epidural use.31 Higher plasma concentrations and a 250 ␮g·kgϪ1·hϪ1. With S(ϩ) ketamine, doses can be longer elimination half-life but decreased maximum reduced to approximately 70% of the dose of racemic plasma concentrations were reported for 48 h after epi- ketamine when continuously administered; its use ends dural as compared with intravenous ketamine. 30 min before wound closure (table 2). It is advisable to Trials investigating intraoperative ketamine as an anal- administer the first bolus doses or the first 20 min of an gesic additive to epidural regimens have reported im- infusion under careful monitoring of patient hemody- proved analgesia and a local anesthetic or opioid-sparing namic response. With reduced nociception, many pa- effect that lasts into the postoperative period (level II tients show declines in blood pressure and heart rate. evidence) (table 3).21,22 Psychotomimetic effects and Further doses are then titrated according to the individ- postoperative nausea and vomiting were similar in ket- ual response. Under general anesthesia, less anesthetic amine-treated and control patients. When epidural sub- will be required when ketamine is used in this manner. anesthetic S(ϩ) ketamine combined with a local anes- After administration of subanesthetic
Load more

Recommended publications
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • Methadone Hydrochloride Tablets, USP) 5 Mg, 10 Mg Rx Only
    ROXANE LABORATORIES, INC. Columbus, OH 43216 DOLOPHINE® HYDROCHLORIDE CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg Rx Only Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists. It is critical to understand the pharmacokinetics of methadone when converting patients from other opioids (see DOSAGE AND ADMINISTRATION). Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. In addition, cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Methadone treatment for analgesic therapy in patients with acute or chronic pain should only be initiated if the potential analgesic or palliative care benefit of treatment with methadone is considered and outweighs the risks. Conditions For Distribution And Use Of Methadone Products For The Treatment Of Opioid Addiction Code of Federal Regulations, Title 42, Sec 8 Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority.
    [Show full text]
  • Opioid Analgesics These Are General Guidelines
    Adult Opioid Reference Guide June 2012 Opioid Analgesics These are general guidelines. Patient care requires individualization based on patient needs and responses. Lower doses should be used initially, then titrated up to achieve pain relief, especially if the patient has not been taking opioids for the past week (opioid naïve). Patients who have been taking scheduled opioids for at least the previous 5 days may be considered “opioid tolerant”. These patients may require higher doses for analgesia. Drug # Route Starting Dose Onset Peak Duration Metabolism Half Life Comments (Adults > 50 Kg) Buprenorphine Trans- 5 mcg/hr q 7 DAYS 17 hr 60 hr 7 DAYS Liver 26 hr Maximum dose = 20 mcg/hr patch dermal Extensively metabolized by CYP3A4 enzymes – watch for Example: Butrans® drug interactions Transdermal patches are not available at UIHC Codeine PO 30 - 60 mg q 4 hr 30 min 1½ hr 6 hr Liver 2 - 4 hr Oral not recommended first-line therapy. Some patients cannot metabolize codeine to active morphine. Fentanyl IM 5 mcg/Kg q 1 - 2 hr 7 - 8 min 20 - 50 min 1 - 2 hr Liver 1 - 6 hr* Give IV slowly over several minutes to prevent chest wall IV 0.25 - 1 mcg/Kg as Immediate 1 - 5 min 30 - 60 min rigidity SQ needed Refer to the formulary for administration and monitoring. May be used in patients with renal impairment as it has no active metabolites. Accumulates in adipose tissue with continuous infusion. Trans- 25 mcg/hr 12 - 24 hr 24 hr 48 - 72 hr Transdermal should NOT be used to treat acute pain.
    [Show full text]
  • Fast Facts and Concepts
    ! FAST FACTS AND CONCEPTS #36 CALCULATING OPIOID DOSE CONVERSIONS Robert Arnold MD and David E Weissman MD Introduction A variety of published conversion tables exist to provide clinicians a rough guide for making calculations when switching between different opioid routes or preparations. Listed below are methods for common conversions using standard published conversion ratios. The examples assume a change in drug or route at a time of stable pain control using equianalgesic doses. See Fast Fact #2 about conversions involving transdermal fentanyl; #75 and #86 about methadone; and #181 about oxymorphone. Caution: Published values in equianalgesic tables should be considered a rough clinical guide when making dose conversions; substantial inter-individual variation exists. The final prescribed dose needs to take into account a patients’ age, renal, pulmonary and hepatic function; their current pain level and opioid side effects such as sedation; as well as prior and current opioid use. Opioid Equianalgesic Conversion Ratios for use with the following examples: Morphine 10 mg parenteral = Morphine 30 mg oral = Hydromorphone 1.5 mg parenteral = Hydromorphone 7.5 mg oral = Hydrocodone 30 mg oral = Oxycodone 20-30 mg oral (see Reference 1). A. Change route, keeping drug the same (e.g. oral to IV morphine) Example: Change 90 mg q12 Extended Release Morphine to Morphine by IV continuous infusion 1. Calculate the 24 hour current dose: 90mg q 12 = 180 mg Morphine/24 hours 2. Use the oral to parenteral equianalgesic ratio: 30 mg PO Morphine = 10 mg IV Morphine 3. Calculate new dose using ratios: 180/30 x 10 = 60 mg IV Morphine/24 hours or 2.5 mg/hour infusion 4.
    [Show full text]
  • Copyright © Keith M. Olson 2017 a Dissertation Submitted to The
    Atypical Opioid Interactions – Development of Selective Mu-Delta Heterodimer Antagonists, Clinical Opioids at Non-Mu Pain Targets and Endogenous Biased Signaling Item Type text; Electronic Dissertation Authors Olson, Keith Mathew Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 05/10/2021 19:11:41 Link to Item http://hdl.handle.net/10150/626669 ATYPICAL OPIOID INTERACTIONS – DEVELOPMENT OF SELECTIVE MU-DELTA HETERODIMER ANTAGONISTS, CLINICAL OPIOIDS AT NON-MU PAIN TARGETS AND ENDOGENOUS BIASED SIGNALING by Keith M. Olson ___________________ Copyright © Keith M. Olson 2017 A Dissertation Submitted to the Faculty of the DEPARTMENT OF CHEMISTRY AND BIOCHEMISTRY In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY WITH A MAJOR IN BIOCHEMISTRY In the Graduate College THE UNIVERSITY OF ARIZONA 2017 2 3 STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of requirements for an advanced degree at the University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that accurate acknowledgment of source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his or her judgment the proposed use of the material is in the interests of scholarship.
    [Show full text]
  • Why Equianalgesic Tables Are Only Part of the Answer to Equianalgesia
    541 Review Article on Opioid Utility the Other Half of Equianalgesia Why equianalgesic tables are only part of the answer to equianalgesia Mary Lynn McPherson Department of Pharmacy Practice and Science, University of Maryland Baltimore, Baltimore, Maryland, USA Correspondence to: Prof. Dr. Mary Lynn McPherson, PharmD, MA, MDE, BCPS. Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, 20 N. Pine Street, S405, Baltimore, Maryland 21201, USA. Email: [email protected]. Abstract: Opioids are an important tool in the management of acute and chronic (cancer and non-cancer) pain. Pain and palliative care practitioners are frequently called upon to switch a patient from one opioid regimen to a different regimen either to gain better pain control, to minimize opioid-related adverse effects, to overcome opioid tolerance, or due to a change in patient status. To this end, equianalgesic tables have been published to guide practitioners in making these calculations. Despite being built on the best data available, equianalgesic tables do not tell the whole story, requiring the practitioner to thoroughly consider the patient’s situation, and unknown variables. A five-step process is presented in this article that espouse a safe and effective way to switch from one opioid regimen to another. Directions for the future include better refinement of the data that informs the equianalgesic table, and perhaps inclusion of opioid utility data. Keywords: Opioids; equianalgesia; equivalency; rotation; switching Submitted Feb 02, 2020. Accepted for publication Feb 20, 2020. doi: 10.21037/apm.2020.03.05 View this article at: http://dx.doi.org/10.21037/apm.2020.03.05 Introduction opioid-responsive (lack of effect).
    [Show full text]
  • Principles of Opioid Management Principles of Opioid Management Hospice Palliative Care Program • Symptom Guidelines
    Hospice Palliative Care Program Symptom Guidelines Principles Of Opioid Management Principles Of Opioid Management Hospice Palliative Care Program • Symptom Guidelines Principles Of Opioid Management Rationale This guideline is adapted for inter-professional primary care providers working in various settings in Fraser Health, British Columbia. Scope This guideline provides recommendations for the assessment and symptom management of adult patients (age 19 years and older) living with advanced life threatening illness and experiencing the symptom of pain and requiring the use of opioid medication to control the pain. This guideline does not address disease specific approaches in the management of pain. Definition of Terms Opioid refers to drugs with morphine like actions, both natural and synthetic. Examples of opioids are: codeine, morphine, hydromorphone, oxycodone, fentanyl and methadone.(1) • Short acting opioid medications are also called immediate release (IR). These can come in oral, suppository, gel or parenteral formulations.(2) • Long acting opioid medications are also called sustained release (SR), controlled release (CR) or extended release (ER). These can come in oral or transdermal formulations.(1) • Total Daily Dose (TDD) is the 24 hour total of a drug that is taken for regular and breakthrough doses.(2) • Steady state is when the rate of drug availability and elimination equal one another.(1) • Breakthrough Dose (BTD) is an additional dose used to control breakthrough pain (a transitory flare of pain that occurs on a background of relatively well controlled baseline pain). It does not replace or delay the next routine dose. BTD is also known as a rescue dose.(2) Opioid titration has traditionally been referred to as adjusting the dosage of an opioid.(3, 4) It requires regular assessment of the patient’s pain, when and why it occurs as well as the amount of medication used in the previous 24 to 72 hour period.(2) Opioid rotation is switching one opioid for another.
    [Show full text]
  • Summary Report of Benefit-Risk Assessment NALDEBAIN
    Summary Report of Benefit-Risk Assessment NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML NEW DRUG APPLICATION Active Ingredient(s) Dinalbuphine sebacate Product Registrant Intega Pte Ltd Product Registration Number SIN16058P Application Route Abridged evaluation Date of Approval 15 December 2020 Copyright © 2021 Health Sciences Authority of Singapore You may download, view, print and reproduce this summary report without modifications for non-commercial purposes only. Except as otherwise provided, the contents of this summary report may not be reproduced, republished, uploaded, posted, transmitted or otherwise distributed in any way without the prior written permission of the Health Sciences Authority. This summary report and its contents are made available on an “as is” basis and the Health Sciences Authority makes no warranty of any kind, whether express or implied. The information in the summary report is provided for general information only and the contents of the summary report do not constitute medical or other professional advice. If medical or other professional advice is required, services of a competent professional should be sought. Table of Contents A INTRODUCTION ............................................................................................................. 3 B ASSESSMENT OF PRODUCT QUALITY ....................................................................... 3 C ASSESSMENT OF CLINICAL EFFICACY ...................................................................... 4 D ASSESSMENT OF CLINICAL SAFETY .........................................................................
    [Show full text]
  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review
    CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN GUIDELINE FOR THE Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAIN Evidence Review The American Pain Society in Conjunction with The American Academy of Pain Medicine EVIDENCE REVIEW APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain TABLE OF CONTENTS Page Introduction 1 Purpose of evidence review ...................................................................... 1 Background 1 Previous guidelines ................................................................................... 2 Scope of evidence review 3 Key questions............................................................................................ 3 Populations................................................................................................ 7 Interventions.............................................................................................. 8 Outcomes.................................................................................................. 8 Conflict of interest............................................................................................. 10 Methods 10 Literature search and strategy................................................................... 10 Inclusion and exclusion criteria.................................................................. 11 Data extraction and synthesis ..................................................................
    [Show full text]
  • Equianalgesic Dosing It's Not Just About the Math
    Equianalgesic Dosing Mechele Fillman, NP Pain It’s not just about the Management math March 2014 Objectives ❖ Discuss the difference of route conversion and opioid rotation ❖ Discuss when it is appropriate to rotate and/or convert an opioid ❖ List 3 considerations when determining an opioid dose Equianalgesic Dose Definitions ❖ Equaianalgesic dose - Defined “as that dose at which two opioids (at steady state) provide approximately the same pain relief.” (Shaheen, Walsh, Lasheen, Davis, & Lagman, 2009) ❖ Usually standardized to 10mg of parenteral morphine ❖ Route conversation - same opioid but different route ❖ Oral morphine to IV morphine ❖ Opioid rotation - different opioid but same route ❖ Oral oxycodone to PO hyromorphone ❖ Potency “refers to the power of a medicinal agent to generate its desired outcome, the dose required to produce a given effect.” (Anderson, Saiers, Abram, & Schlicht, 2000) Equianalgesic Dose Definitions ❖ Incomplete cross-tolerance - refers to the development of tolerance to the effects of other structurally similar drugs in the same pharmacologic class after long term exposure. This effect is rarely complete in opioids. Complete cross tolerance can develop as evidenced by the lack of analgesic effect. ❖ Bidirectional conversions -- the conversion ratio will change depending on the direction of the conversion. (eg. morphine to methadone versus methadone to morphine) ❖ Opiate--narcotic analgesic derived from a opium poppy, not synthetic, eg. heroin ❖ Opioid--narcotic analgesic derived at least in part synthetically,
    [Show full text]
  • Replacement of Current Opioid Drugs Focusing on MOR-Related Strategies
    JPT-107519; No of Pages 17 Pharmacology & Therapeutics xxx (2020) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Replacement of current opioid drugs focusing on MOR-related strategies Jérôme Busserolles a,b, Stéphane Lolignier a,b, Nicolas Kerckhove a,b,c, Célian Bertin a,b,c, Nicolas Authier a,b,c, Alain Eschalier a,b,⁎ a Université Clermont Auvergne, INSERM, CHU, NEURO-DOL Pharmacologie Fondamentale et Clinique de la douleur, F-63000 Clermont-Ferrand, France b Institut ANALGESIA, Faculté de Médecine, F-63000 Clermont-Ferrand, France c Observatoire Français des Médicaments Antalgiques (OFMA), French monitoring centre for analgesic drugs, CHU, F-63000 Clermont-Ferrand, France article info abstract Available online xxxx The scarcity and limited risk/benefit ratio of painkillers available on the market, in addition to the opioid crisis, warrant reflection on new innovation strategies. The pharmacopoeia of analgesics is based on products that are often old and derived from clinical empiricism, with limited efficacy or spectrum of action, or resulting in Keywords: an unsatisfactory tolerability profile. Although they are reference analgesics for nociceptive pain, opioids are sub- Analgesia ject to the same criticism. The use of opium as an analgesic is historical. Morphine was synthesized at the begin- Mu opioid receptors (MORs) ning of the 19th century. The efficacy of opioids is limited in certain painful contexts and these drugs can induce Opioid adverse side effects potentially serious and fatal adverse effects. The current North American opioid crisis, with an ever-rising number Opioid abuse and misuse of deaths by opioid overdose, is a tragic illustration of this.
    [Show full text]
  • The Opioid Systems and the Role of Glial Cells in the Effects of Opioids
    Review paper Joanna Mika Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland The opioid systems and the role of glial cells in the effects of opioids Abstract Understanding of the molecular mechanisms in the opioid systems in chronic pain should produce new, more effective methods of the pharmacotherapy of pain. Pharmacological suppression of glial activation in combi- nation with morphine, methadone, fentanyl and buprenorphine may be an important aspect of pain therapy. Long-term use of the classical opioid analgesics in patients with chronic pain processes results in tolerance, and the search of new treatment strategies based on the recognised mechanisms of pain is an important clinical and scientific issue. Key words: opioid peptides, opioid receptors, opioids, morphine, glia, minocycline, pentoxifylline, ibudilast Adv. Pall. Med. 2008; 7: 185–196 The opioid systems certain peptides derived from prodynorphin exert non-opioid effects in addition to opioid effects and for this reason are classified as non-opioid neuropep- Opioid peptides tides [1–8]. In 1997 Zadina et al. discovered new Opioid peptides are derived from three precur- endogenous peptides with a very high affinity and sors: proopiomelanocortin (POMC), proenkephalin selectivity to the MOP opioid receptor. Due to their and prodynorphin. Proopiomelanocortin is the pre- selective effect on the receptor through which mor- cursor of the opioid peptides a-, b- and g-endorphin phine exerts its actions they have been called endo- and of the non-opioid peptides ACTH, a- and b- morphins [9]. While nothing is known about their MSH, CLIP and b-LPH. Of these peptides, the best precursors and genes, their location in the brain- investigated one is b-endorphin, which plays an im- stem, spinal cord and nerve ganglia as well as their portant role in stress, transmission of nociceptive coexistence with the MOP opioid receptor suggest stimuli, hormonal regulation and in the regulation an important role in nociception [10].
    [Show full text]